The airway management devices market size was valued at USD 1,580 million in 2019 and is expected to grow with a CAGR of 5.2%.
The airway control device is a set of medical treatments to prevent patients from experiencing airway obstruction. In patients, this device ensures an open pathway that enables the transfer of gas between the lungs of a patient and the environment. Different products such as laryngeal mask airways, oropharyngeal airways, nasopharyngeal airways, and tracheal intubation are used in supplying airways in patients undergoing hospital anesthesia procedures. These devices are known to be used in anesthesia, cardiopulmonary resuscitation, emergency medicine, neonatology, and several other areas.
| Report Metric | Details |
|---|---|
| Base Year | 2020 |
| Study Period | 2019-2029 |
| Forecast Period | 2023-2031 |
| CAGR | 5.2% |
| Market Size | USD 1,580 million in 2019 |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
| Geographies Covered |
|
Rising cases of respiratory emergencies and chronic obstructive pulmonary disease (COPD) are the main factors driving the demand for airway management devices. Around 65 million people suffer from mild to extreme COPD, as per reports by the World Health Organization. In addition, COPD is expected to be the world's third-largest cause of death.Also, as per the CDC (Centers for Disease Control and Prevention) report, in 2018, about 9 million adults were diagnosed with chronic bronchitis. This high prevalence, along with an uptick in anesthesia use, is expected to boost demand for advanced devices due to the rise in surgeries.
It is estimated that the rising need for emergency care for chronic illnesses as well as protracted lung-associated treatments in children and adults will further stimulate market growth. Furthermore, the rapid surge in the aging population that is more prone to respiratory disorderis contributing immensely towards the high need for airway management devices. According to the United Nations study released in 2017, the geriatric population was about 962 million and is projected to reach 2.1 billion by 2050.
In neonatology, airway management devices have wide-ranging applications for managing the airway in babies. Continually growing occurrence of preterm birth has necessitated the need for effective airway management. Soaring mortality rates for neonates, coupled with growing numbers of preterm births with respiratory disorders, are the key factors driving the market growth. About 15 million preterm babies are born annually (before 37 weeks of gestation), which is more than 1 out of 10 children, as per the WHO reports in 2018, and this number is increasing exponentially per year. Premature birth rates range from 5 to 18 % of born infants in 184 nations.
Compared with adults, pediatric patients have different anatomic and physiological structures. It's also difficult to assess and control pediatric airways. Yet recent developments in techniques and technology can include ease in the control of pediatric airways. Products such as 'Modern laryngeal mask airway' and 'proseal LMA' are achieving momentum in the pediatric airway management marketplace. The performance of Classic LMA in achieving sufficient ventilation in children is about 95–98%. Advancements in airway control technologies for pediatric airway management are projected to fuel airway management product development over the predicted time span.
The U.S. to Be at the Forefront of North America's Airway Management Devices Market
North America holds the largest share in the Airway management devices market, owing to the high incidence of chronic obstructive pulmonary disease and asthma, coupled with the rising number of the geriatric population base. According to the U.S Census Bureau's Statistics, as of 2017, the total number of people aged between 65 years and older exceeded 50 million that are most susceptible to chronic diseases, which require immediate ventilation. Chronic obstructive pulmonary disease (COPD) is the third leading cause of death, with a total of 384 million people suffering from COPD per year, as per the United for Lung Health 2019. Lung cancer has been the deadliest disease in the world, with 1.76 million deaths per year. In addition, 10 million people develop tuberculosis, and 334 million people per year suffer from asthma, further surging the demand for airway control equipment.
The U.S. and Canada are two key regions that have experienced large-scale adoption of such devices. The surge in pollution rate, along with the growing number of cases related to respiratory troubles, even for neo-natal care, are the prime reasons for surging the demand for airway management devices in North America. The U.S. market will witness significant growth over the forecast period, owing to the presence of favorable reimbursement policies, rising R&D expenditure in the healthcare sector, and the increasing prevalence of COPD and chronic disorders. As per the WHO's statistics, around 12.7 to 14.7 million adults suffer from COPD in the U.S.Furthermore, the strong presence of market players will boost the market growth in North America. GE Healthcare, a U.S.-based medical device company, offers ventilators, CARESCAPE R860, through its healthcare systems segment. Similarly, ResMed Inc. provides both types of ventilators, invasive, and non-invasive ventilators.
Japan to Hold the Largest Share in Asia-Pacific's Airway Management Devices Market
Asia-Pacific is considered to be the most lucrative regional market for airway management devices, owing to the increasing cases of chronic respiratory diseases and rising healthcare expenditure and tax benefits provided by the regional governments. Moreover, infrastructural development and improved healthcare policies promoting better care provision will drive the regional market further. China's Five-Year Plan from 2016 includes various healthcare reforms that support the expansion of the market within the region. According to various economic reports, over the next seven years, healthcare spending per capita is expected to rise in this region, providing huge growth opportunities for the global airway management devices market.
The economic and social commission for Asia and the Pacific (ESCAP) reports that the geriatric population in APAC was nearly about 617.1 million in 2015, accounting for more than half of the global geriatric population and is assumed that, by 2050, it might account for virtually two-thirds of the population. Hence, due to the fact that asthma is an extensively prevalent disease found in people above 65 years, the growing geriatric population is expected to drive the market growth over the forecast period. Japan is expected to hold the largest market share, owing to the growing geriatric population, increased incidences of infectious respiratory disorders due to environmental pollution, and changing regulatory scenarios in the country.
The supraglottic segment is predicted to grow with an exponential CAGR during the forecast period. The growing demand for these products is presumed to be a consequence of its associated benefits. The most significant benefit includes easy tracheal placement, resulting in enhanced patient safety, which is believed to drive the preference of patients as well as anaesthesiologists toward these devices.Laryngeal mask airways (LMA) are most often preferred type on supraglottic devices as they can be used conveniently in hospitals, ASCs, and other places during the operation. Nevertheless, its demand is growing at a rapid pace,owing to its improved success rate coupled with cost-effectiveness. Additionally, supraglottic devices, such as indirect video laryngoscopes, are widely being used in an extensive range of clinical applications, further driving the market growth.
The anesthesia segment dominated the market on account of the surging preference and use of these devices by anaesthesiologists in operative surgical procedures. The growing adoption is believed to benefit from high efficiency in airway clearance and adequate ventilation maintenance, without sacrificing patient safety during operating procedures. Furthermore, it is believed that a growing number of product launches and acquisition strategies pursued by prominent market players drive the market growth.
The home care segment is estimated to register the fastest CAGR growth during the estimated period on account of increased out-of-pocket healthcare spending, rise in per capita revenue, growing awareness among patients and doctors about advanced technology, increased prevalence of respiratory disorders, and increased adoption of home healthcare products. As per the Forum of International Respiratory Societies (FIRS) survey, around 100 million adults are suffering from a sleep-breathing disorder, over 235 million people have asthma, and around 200 million are diagnosed with COPD.
The prevalence of respiratory diseases is high in developed as well as developing countries, owing to increased air pollution, occupational exposures, and smoking causing obstruction to the airways. The aforementioned factors will accelerate the home care airway management device segment growth during the forthcoming years. In 2017, Air Liquide (the U.S.) acquired Sogo Sangyo Kabushiki Kaisha (Japan) and OxyMaster (Columbia) to enlarge its home ventilation healthcare portfolio across APAC and Latin America.
